Video

Clinical Practice Pearls and the Future of SCLC

Author(s):

Charu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Related Videos
4 experts are featured in this series.
Sandip P. Patel, MD
Related Content
FDA
January 10th 2025

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 7th 2025

Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.
January 4th 2025

The OncFive: Top Oncology Articles for the Week of 12/29

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 3rd 2025

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC